NCT06056895View on ClinicalTrials.gov

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

April 30, 2027

Conditions
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Clinical Stage IV Merkel Cell Carcinoma AJCC v8Merkel Cell Carcinoma
Interventions
PROCEDURE

Biopsy

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT/MRI

PROCEDURE

Magnetic Resonance Imaging

Undergo CT/MRI

BIOLOGICAL

Retifanlimab

Given IV

DRUG

Tuparstobart

Given IV

DRUG

Verzistobart

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Incyte Corporation
All Listed Sponsors
collaborator

Incyte Corporation

INDUSTRY

lead

University of Washington

OTHER